Pharmafile Logo
Pharmafocus logo
Advanced Search

BMS

Showing 15 posts of 286 posts found.

Bristol-Myers Squibb chooses UCLA as latest research partner

December 14, 2015
Manufacturing and Production, Research and Development BMS, Bristol-Myers Squibb, University of California Los Angeles, rare malignancies, ucla

Pharma firm Bristol-Myers Squibb is entered into a new collaboration agreement with the University of California Los Angeles (UCLA) as …

News
Empliciti logo

FDA approves BMS and AbbVie’s Empliciti for multiple myeloma

December 1, 2015
Manufacturing and Production, Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Empliciti, FDA, elotuzumab, multiple myeloma

The US healthcare regulator has approved Empliciti – a multiple myeloma treatment co-developed by Bristol-Myers Squibb and AbbVie. The FDA …

News
BMS building

Bristol-Myers Squibb enters academic R&D tie-up

November 4, 2015
Research and Development BMS, Bristol-Myers Squibb, Cardioxy, John Hopkins, acquisition, immunooncology, job losses

Bristol-Myers Squibb and The Johns Hopkins University have entered into a collaboration agreement, as part of the pharma firm’s rare …

News
Yervoy

FDA approves Bristol-Myers Squibb’s skin cancer drug

October 29, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, Yervoy, ipilumumab, melanoma

The FDA has recommended Bristol-Myers Squibb’s cancer drug Yervoy (ipilimumab) for the adjuvant treatment of patients with melanoma. The drug, …

News

NICE to recommend three new treatments for hep C

October 16, 2015
Medical Communications AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, Viekirax, daklinza, harvoni, hepatitis C

NICE has recommended Bristol-Myers Squibb’s Daklinza, Gilead’s Harvoni and AbbVie’s Viekirax, with or without Exviera, as treatments for some adults …

News
T-cell

$350m collaboration deal for BMS and Five Prime Therapeutics

October 15, 2015
Research and Development BMS, Bristol-Myers Squibb, R&D, five prime, immuno-oncology, tumours

Bristol-Myers Squibb has signed a collaboration agreement with the US biotech firm Five Prime Therapeutics, for a Colony Stimulating Factor …

News
keytruda

FDA approves Merck’s Keytruda for advanced NSC lung cancer

October 5, 2015
Research and Development, Sales and Marketing BMS, NSCL, keytruda, lung cancer, merck sharp and dohme, opdivo

The US Food and Drug Administration has granted accelerated approval for Merck’s Keytruda (pembrolizumab) to treat patients with advanced (metastatic) …

News

FDA grants Opdivo breakthrough status for kidney cancer

September 18, 2015
Research and Development, Sales and Marketing BMS, Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, Kidney cancer, immuno-oncology, immunotherapy, nivolumab, opdivo, renal cell carcinoma

The FDA has given Bristol-Myers Squibb’s immuno-oncology drug Opdivo Breakthrough Therapy Designation as a kidney cancer treatment. The FDA’s decision …

News

Bristol-Myers Squibb makes big pharma deals

September 1, 2015
Manufacturing and Production BMS, Bristol-Myers Squibb, PRM-151, Promedior, QIMR, fibrosis, idiopathic pulmonary fibrosis, immuno-oncology, myelofibrosis

Bristol-Myers Squibb is flexing its muscles in respiratory disease, by signing a deal to acquire the exclusive right to acquire …

News
Opdivo

Bristol-Myers Squibb launches Opdivo in the UK for lung cancer

August 12, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, NSCLC, immunotherapy, lung cancer, non small cell lung cancer, non-small cell lung cancer, opdivo

The immuno-oncology drug Opdivo is available in the UK for people with lung cancer, after Bristol-Myers Squibb launched the drug …

News

BMS to trial Opdivo in solid tumours

July 30, 2015
Research and Development BMS, Bristol-Myers Squibb, Kyowa Hakko Kirin, Poteligeo, mogamulizumab, nivolumab, opdivo, solid tumours

Bristol-Myers Squibb will begin early-phase trials of its immuno-oncology treatment Opdivo with other cancer treatments, to see if the combination …

News
Daklinza

NICE restricts access to new hepatitis C treatments

July 29, 2015
Sales and Marketing AbbVie, BMS, Bristol-Myers Squibb, Exviera, Gilead, NICE, daklinza, harvoni, hepatits C

NICE has recommended three new treatment options for hepatitis C in draft guidance – but has been criticised for excluding …

News
Opdivo

BMS halts Opdivo kidney cancer trial early

July 22, 2015
Research and Development BMS, Bristol-Myers Squibb, European Commission, Kidney cancer, opdivo, renal cell carcinoma

Bristol-Myers Squibb has stopped its Phase III study of its immunotherapy drug Opdivo in people with kidney cancer early after …

News

Opdivo launched in the UK for skin cancer

July 2, 2015
Sales and Marketing BMS, Bristol-Myers Squibb, EMA, Early Access to Medicines Scheme, MHRA, eams, melanoma, opdivo, skin cancer

Bristol-Myers Squibb has launched its cancer immunotherapy treatment Opdivo in the UK for patients with advanced skin cancer. Opdivo (nivolumab) …

News

BMS’ Opdivo accepted to UK early access scheme

June 30, 2015
Sales and Marketing BMS, Cancer, NSCLC, eams, keytruda, opdivo

Bristol-Myers Squibb has scored another first with its new-generation oncology therapy Opdivo, which has become the first lung cancer drug …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026